Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive
NICE is unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults
Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE is unable to make a recommendation on dupilumab (Dupixent) for treating chronic rhinosinusitis with nasal polyps because Sanofi did not provide an evidence
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults
NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence
NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1
Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic
NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not
NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non
NICE is unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults
Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults